Here’s a roundup of the latest coronavirus-related news from this week.
Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.
Gilead has now asked the FDA to rescind its orphan drug status for the potential COVID-19 therapy.
Health care providers should look out for more than just respiratory diagnoses in patients when it comes to influenza-associated complications, according to a recent study.
In a joint statement, the American Medical Association (AMA), American Pharmacists Association (APhA), and American Society of Health-System Pharmacists (ASHP) have communicated concerns regarding the inappropriate ordering, prescribing, or dispensing of treatments for COVID-19.
Tissue plasminogen activator, which is used to treat blood clots, may help severely ill patients with COVID-19 who are in respiratory failure, according to a new paper.
CVS Caremark’s new quantity limits will not affect members who are already receiving these medications for their approved uses.
Convalescent plasma, hydroxychloroquine, and remdesivir among the potential COVID-19 treatment pathways being pursued.
A study investigated the use of lopinavir-ritonavir for the potential treatment of hospitalized patients with severe COVID-19.
The trials demonstrated a significant decrease in 24-hour coughs per hour versus placebo at 12 and 24 weeks.